Search Results - "GOTTESMAN, M. H"

  • Showing 1 - 19 results of 19
Refine Results
  1. 1

    A profile of multiple sclerosis: The New York State Multiple Sclerosis Consortium by Jacobs, L D, Wende, K E, Brownscheidle, C M, Apatoff, B, Coyle, P K, Goodman, A, Gottesman, M H, Granger, C V, Greenberg, S J, Herbert, J, Krupp, L, Lava, N S, Mihai, C, Miller, A E, Perel, A, Smith, C R, Snyder, D H

    Published in Multiple sclerosis (01-10-1999)
    “…We have obtained a current profile of multiple sclerosis (MS) in New York State through a centralized patient registry and standardized data collection…”
    Get full text
    Journal Article
  2. 2

    Neutralizing antibodies to 500 μg interferon beta-1b: 28-month results of the IDEAS extension trial by Gottesman, MH, Friedman-Urevich, S., Boylan, E., Cheng, D.

    Published in Multiple sclerosis (01-01-2010)
    “…The Interferon Dose Escalation Assessment of Safety extension trial monitored neutralizing antibodies to interferon beta-1b in patients who currently or had…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Modified Brown-Séquard syndrome following coronary artery bypass graft : case report by GOTTESMAN, M. H, SARAYA, I, TENTI, F

    Published in Paraplegia (01-03-1992)
    “…A 75 year old man underwent a triple coronary artery bypass graft performed with intra-aortic balloon pump assistance. Left leg weakness developed on the first…”
    Get full text
    Journal Article
  5. 5
  6. 6

    The CVC removal distress syndrome: an unappreciated complication of central venous catheter removal by Kim, D K, Gottesman, M H, Forero, A, Han, D, Myers, D W, Forlenza, R, Golzarian, J

    Published in The American surgeon (01-04-1998)
    “…The removal of a central venous catheter (CVC) can be complicated by rare but potentially life-threatening neurocardiopulmonary distress. The clinical courses…”
    Get more information
    Journal Article
  7. 7

    Cardiac arrest caused by trigeminal neuralgia by Gottesman, M H, Ibrahim, B, Elfenbein, A S, Mechanic, A, Hertz, S

    Published in Headache (01-06-1996)
    “…A 67-year-old man with a 12-year history of trigeminal neuralgia experienced multiple fainting episodes preceded by right facial pain. One episode resulted in…”
    Get more information
    Journal Article
  8. 8
  9. 9
  10. 10

    Longitudinal correlates of fatigue in multiple sclerosis by Patrick, E, Christodoulou, C, Krupp, LB

    Published in Multiple sclerosis (01-02-2009)
    “…Objective To determine the predictors of longitudinal changes in fatigue based on pain, mood, and neurological impairment across multiple sclerosis (MS)…”
    Get full text
    Journal Article
  11. 11

    Neutralizing antibodies to 500 kg interferon beta-1b: 28-month results of the IDEAS extension trial by Gottesman, M H, Friedman-Urevich, S, Boylan, E, Cheng, D

    Published in Multiple sclerosis (01-01-2010)
    “…The Interferon Dose Escalation Assessment of Safety extension trial monitored neutralizing antibodies to interferon beta-1b in patients who currently or had…”
    Get full text
    Journal Article
  12. 12

    Interferon beta-1b (betaseron/betaferon) is well tolerated at a dose of 500 microg: interferon dose escalation assessment of safety (IDEAS) by Gottesman, M H, Friedman-Urevich, S

    Published in Multiple sclerosis (01-06-2006)
    “…The approved interferon beta-1b (Betaseron/Betaferon) dose is 250 microg (8 MIU) administered subcutaneously (sc) every other day (eod). Clinical trial data…”
    Get full text
    Journal Article
  13. 13

    Interferon beta-1b (Betaseron®/Betaferon®) is well tolerated at a dose of 500 mg: interferon dose escalation assessment of safety (IDEAS) by Gottesman, M H, Friedman-Urevich, S

    Published in Multiple sclerosis (01-06-2006)
    “…The approved interferon beta-1b (Betaseron®/Betaferon®) dose is 250 mg (8 MIU) administered subcutaneously (sc) every other day (eod). Clinical trial data…”
    Get full text
    Journal Article
  14. 14

    Neutralizing antibodies to 500 microg interferon beta-1b: 28-month results of the IDEAS extension trial by Gottesman, M H, Friedman-Urevich, S, Boylan, E, Cheng, D

    Published in Multiple sclerosis (01-01-2010)
    “…The Interferon Dose Escalation Assessment of Safety extension trial monitored neutralizing antibodies to interferon beta-1b in patients who currently or had…”
    Get full text
    Journal Article
  15. 15

    Interferon beta-1b (Betaseron®/Betaferon®) is well tolerated at a dose of 500 [phi]g: interferon dose escalation assessment of safety (IDEAS) by Gottesman, M H, Friedman-Urevich, S

    Published in Multiple sclerosis (01-06-2006)
    “…The approved interferon beta-1b (Betaseron/Betaferon) dose is 250 microg (8 MIU) administered subcutaneously (sc) every other day (eod). Clinical trial data…”
    Get full text
    Journal Article
  16. 16

    Neutralizing antibodies to 500 [mu]g interferon beta-1b: 28-month results of the IDEAS extension trial by Gottesman, MH, Friedman-Urevich, S, Boylan, E, Cheng, D

    Published in Multiple sclerosis (01-01-2010)
    “…The Interferon Dose Escalation Assessment of Safety extension trial monitored neutralizing antibodies to interferon beta-1b in patients who currently or had…”
    Get full text
    Journal Article
  17. 17

    A profile of multiple sclerosis: The New York State Multiple Sclerosis Consortium by Jacobs, L.D., Wende, K.E., Brownscheidle, C.M., Apatoff, B., Coyle, P.K., Goodman, A., Gottesman, M.H., Granger, C.V., Greenberg, S.J., Herbert, J., Krupp, L., Lava, N.S., Mihai, C., Miller, A.E., Perel, A., Smith, C.R., Snyder, D.H.

    Published in Multiple sclerosis (01-05-1999)
    “…We have obtained a current profile of multiple sclerosis York State through a centralized patient registry and standardized data collection instrument…”
    Get full text
    Journal Article
  18. 18

    Tissue plasminogen activator for acute stroke in everyday clinical practice by Wirkowski, Elzbieta J., Gottesman, Malcolm H., Mazer, Cynthia, Brody, Gerald M., Manzella, Stephanie M.

    “…Thrombolysis for acute ischemic stroke has become a reality. The aim of our study was to assess the opportunity and practicality of establishing acute stroke…”
    Get full text
    Journal Article
  19. 19